| |
|
|
|
Marriott San Diego La Jolla, La Jolla, CA
October 6-8, 2014
Digital PCR's ability to precisely quantitate, identify mutations, copy number variations, and do gene expression analysis is creating waves across the diagnostics landscape. It is well suited for single-cell analysis and shows promise to become a superior tool in the clinic due to its capacity to work with small amounts of sample. The Third Annual Digital PCR event will bring together industry visionaries and early adopters to discuss digital PCR's capabilities, limitations, and future applications. Researchers will examine applications in cancer biomarker and rare mutation detection, non-invasive fetal DNA analysis, and infectious disease quantification, particularly in HIV. Novel digital PCR devices from startups and academic labs will be showcased. Other topics to be addressed include digital PCR integration with existing technologies, solutions for processing difficult samples as well as increasing sample throughput, and guidelines and best practices for digital detection.
|
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute (CHI) |
|
|
Invited Speakers:
|
|
- Jim Huggett, BSc (Hons), Ph.D., Science Leader, Nucleic Acid Metrology, Molecular & Cell Biology, LGC
- Daniel T. Chiu, Ph.D., A. Bruce Montgomery Professor, Chemistry; Endowed Professor, Analytical Chemistry; Professor, Bioengineering, University of Washington, Seattle
- Jason H. Bielas, Ph.D., Associate Member, Translational Research Program, Fred Hutchinson Cancer Research Center (FHCRC); Affiliate Assistant Professorship, Department of Pathology, University of Washington
- Stephen Bustin, Ph.D., Professor of Allied Health and Medicine, Anglia Ruskin University
- Ross Haynes, Biological Science Technician, Biochemical Science Division, National Institute of Standards and Technology (NIST)
- Stefan Rödiger, Ph.D., Group Leader InnoProfile Group “Image-Based Assays”, Brandenburg University of Technology
- Jo Vandesompele, Ph.D., CEO, Biogazelle; Professor, Ghent University
- Jonathan Frampton, Ph.D., Global Product Manager, Horizon Diagnostics
- Reinhold Pollner, Ph.D., Director, Clinical Trial Assay Development, Genoptix Medical Laboratory, a Novartis Company
- Chris Karlovich, Ph.D., Principal Scientist, Molecular Diagnostics, Clovis Oncology
- Cloud P. Paweletz, Ph.D., Head, Translational Research Laboratory; Biomarker Lead, Belfer Institute for Applied Cancer Science, Dana Farber Cancer Institute
- Rachel Tam, Senior Research Associate, Clinical Assay Development, Oncology Biomarker Development, Genentech, Inc.
- Rory L. Cochran, Ph.D. Candidate, Ben Ho Park Lab, Graduate Program In Cellular & Molecular Medicine, Johns Hopkins University School of Medicine
- Hanlee P. Ji, M.D., Assistant Professor, Medicine, Division of Oncology, Stanford University School of Medicine
- Ali Azizi, Ph.D., Scientist, Adjunct Professor, Microbiology and Virology, Analytical Research and Development, sanofi pasteur
- Douglas Sanders, Ph.D., Senior Scientist, Novartis
- Ekkehard Schütz, M.D., Ph.D., CTO, Senior Vice President, Research, Chronix Biomedical, Inc.
- Mary Alikian, Imperial Molecular Pathology, Imperial Healthcare Trust, Hammersmith Hospital; Centre for Haematology, Faculty of Medicine, Imperial College London
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
---
|
|
|
|
|
|
|
|
Registration:
|
|
Register Now
|
|
|
E-mail:
|
|
kwaterman@healthtech.com
|
|
|
|
|
|
|
|
|